Trial reportThe Journal of clinical endocrinology and metabolism2013
Dipeptidyl peptidase IV inhibition does not adversely affect immune or virological status in HIV infected men and women: a pilot safety study.
Trial report in The Journal of clinical endocrinology and metabolism, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01093651 (A Blinded Randomized Controlled Pilot Immunologic and Virologic Safety Trial of an FDA-approved DPPIV-inhibitor in HIV+ Men and Women), which is not on this map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Blinded Randomized Controlled Pilot Immunologic and Virologic Safety Trial of an FDA-approved DPPIV-inhibitor in HIV+ Men and Women
Who cites it
21 citing papers in PubMed, 37 citations in OpenAlex.
- Effects of dipeptidyl peptidase-4 inhibitor linagliptin versus sulphonylurea glimepiride on systemic haemodynamics in overweight patients with type 2 diabetes: A secondary analysis of an 8-week, randomized, controlled, double-blind trial.Diabetes, obesity & metabolism · 2020Trial
- Plasma levels of DPP4 activity and sDPP4 are dissociated from inflammation in mice and humans.Nature communications · 2020Trial
- A Randomized, Double-blinded, Placebo-controlled Trial of Sitagliptin for Reducing Inflammation and Immune Activation in Treated and Suppressed Human Immunodeficiency Virus Infection.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019Trial
- Vildagliptin reduces plasma stromal cell-derived factor-1α in patients with type 2 diabetes compared with glimepiride.Journal of diabetes investigation · 2017Trial
- Trial
- Sitagliptin Reduces Inflammation and Chronic Immune Cell Activation in HIV+ Adults With Impaired Glucose Tolerance.The Journal of clinical endocrinology and metabolism · 2015Trial
- The role of DPP4 in viral infections: from receptor biology to antiviral target.Archives of virology · 2026Review
- Dipeptidyl Peptidase 4 Inhibitors: Novel Therapeutic Agents in the Management of Type II Diabetes Mellitus.Pharmacoepidemiology and drug safety · 2025Review
- Review
- Efficacy of Dulaglutide in a Patient With Type 2 Diabetes, High Cardiovascular Risk, and HIV: A Case Report.Frontiers in endocrinology · 2022Article
- Systemic DPP4/CD26 is associated with natural HIV-1 control: Implications for COVID-19 susceptibility.Clinical immunology (Orlando, Fla.) · 2021Article
- Diabetes in People with HIV.Current diabetes reports · 2021Review
- Effects of the Antidiabetic Drugs Evogliptin and Sitagliptin on the Immune Function of CD26/DPP4 in Th1 Cells.Biomolecules & therapeutics · 2021Article
- No significant association between dipeptidyl peptidase-4 inhibitors and adverse outcomes of COVID-19.World journal of clinical cases · 2020Article
- Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus.Nature reviews. Endocrinology · 2020Review
- Dipeptidyl peptidase 4 inhibitors and their potential immune modulatory functions.Pharmacology & therapeutics · 2020Review
- Diabetes and HIV.Current diabetes reports · 2018Review
- Atherosclerotic Cardiovascular Disease and Anti-Retroviral Therapy.Current HIV/AIDS reports · 2016Review
- Combination immunotherapies for type 1 diabetes mellitus.Nature reviews. Endocrinology · 2015Review
- Epidemiology and management of antiretroviral-associated cardiovascular disease.The open AIDS journal · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
contextPeople infected with HIV have a higher risk for developing insulin resistance, diabetes, and cardiovascular disease than the general population. Dipeptidyl peptidase IV (DPP4) inhibitors are glucose-lowering medications with pleiotropic actions that may particularly benefit people with HIV, but the immune and virological safety of DPP4 inhibition in HIV is unknown.
objectiveDPP4 inhibition will not reduce CD4+ T lymphocyte number or increase HIV viremia in HIV-positive adults.
designThis was a randomized, placebo-controlled, double-blind safety trial of sitagliptin in HIV-positive adults.
settingThe study was conducted at an academic medical center.
participantsTwenty nondiabetic HIV-positive men and women (9.8 ± 5.5 years of known HIV) taking antiretroviral therapy and with stable immune (625 ± 134 CD4+ T cells per microliter) and virological (<48 copies HIV RNA per milliliter) status.
interventionThe intervention included sitagliptin (100 mg/d) vs matching placebo for up to 24 weeks.
main outcome measuresCD4+ T cell number and plasma HIV RNA were measured every 4 weeks; fasting serum regulated upon activation normal T-cell expressed and secreted (RANTES), stromal derived factor (SDF)-1α, Soluble TNF receptor II, and oral glucose tolerance were measured at baseline, week 8, and the end of study. ANOVA was used for between-group comparisons; P < .05 was considered significant.
resultsCompared with placebo, sitagliptin did not reduce CD4+ T cell count, plasma HIV RNA remained less than 48 copies/mL, RANTES and soluble TNF receptor II concentrations did not increase. SDF1α concentrations declined (P < .0002) in the sitagliptin group. The oral glucose tolerance levels improved in the sitagliptin group at week 8.
conclusionsDespite lowering SDF1α levels, sitagliptin did not adversely affect immune or virological status, or increase immune activation, but did improve glycemia in healthy, nondiabetic HIV-positive adults. These safety data allow future efficacy studies of sitagliptin in HIV-positive people with cardiometabolic complications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.